CA
ARCT icon

CoreCap Advisors’s Arcturus Therapeutics ARCT Stock Holding History

CoreCap Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-75
Closed -$976 – 2799
2025
Q2 		$976 Sell
75
-291
-80% -$3.44K ﹤0.01% 2422
2025
Q1 		$3.88K Buy
366
+291
+388% +$4.62K ﹤0.01% 2163
2024
Q4 		$1.27K Sell
75
-25
-25% -$471 ﹤0.01% 2327
2024
Q3 		$2.32K Hold
100
– – ﹤0.01% 2156
2024
Q2 		$2.44K Buy
+100
New +$3.03K ﹤0.01% 1286

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

CoreCap Advisors's ARCT Position: Q3 2025 in Review

CoreCap Advisors sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 75 shares — an estimated $976 sold.

CoreCap Advisors first reported a position in ARCT in Q2 2024 and held it in 5 quarters. The position peaked at $3.88K in Q1 2025. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • CoreCap Advisors reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • CoreCap Advisors sold 75 Arcturus Therapeutics shares in Q3 2025, an estimated $976.
  • CoreCap Advisors first reported a position in Arcturus Therapeutics in Q2 2024 and held it in 5 quarters.
  • CoreCap Advisors's Arcturus Therapeutics position peaked at $3.88K in Q1 2025.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on CoreCap Advisors's 13F filing for Q3 2025, filed 22 Oct 2025.